Compare IHS & VERA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | IHS | VERA |
|---|---|---|
| Founded | 2001 | 2016 |
| Country | United Kingdom | United States |
| Employees | N/A | N/A |
| Industry | Telecommunications Equipment | Biotechnology: Pharmaceutical Preparations |
| Sector | Telecommunications | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.5B | 2.9B |
| IPO Year | 2021 | 2021 |
| Metric | IHS | VERA |
|---|---|---|
| Price | $8.21 | $40.25 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 7 | 10 |
| Target Price | $8.11 | ★ $81.30 |
| AVG Volume (30 Days) | ★ 2.3M | 1.1M |
| Earning Date | 03-16-2026 | 05-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $3.90 | N/A |
| Revenue Next Year | $2.64 | $416.83 |
| P/E Ratio | $5.85 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $4.21 | $18.53 |
| 52 Week High | $8.95 | $56.05 |
| Indicator | IHS | VERA |
|---|---|---|
| Relative Strength Index (RSI) | 54.47 | 47.01 |
| Support Level | $7.82 | $37.36 |
| Resistance Level | $8.21 | $43.21 |
| Average True Range (ATR) | 0.10 | 2.51 |
| MACD | 0.00 | 0.18 |
| Stochastic Oscillator | 60.00 | 50.58 |
IHS Holding Ltd is an independent owner, operator, and developer of shared telecommunications infrastructure. The company provides telecommunications infrastructure to its customers, who are MNOs, who in turn provide wireless voice and data services to their end-users. Its geographical segments are Nigeria, Sub-Saharan Africa, the Middle East and North Africa (MENA), and Latin America (Latam). The majority of its revenue is derived from Nigeria.
Vera Therapeutics Inc is a clinical stage biotechnology company. It is focused on developing and commercializing transformative treatments for patients with serious immunological diseases. The company's product candidate is atacicept, a fusion protein self-administered as a subcutaneous injection once weekly that blocks both B lymphocyte stimulator and a proliferation-inducing ligand, which stimulate B cells and plasma cells to produce autoantibodies contributing to certain autoimmune diseases.